IJCM  Vol.11 No.5 , May 2020
RETRACTED: The Relationship between BRAF V600E Mutation and the Clinicopathological Features of the Papillary Thyroid Carcinoma
Abstract: Short Retraction Notice International Journal of Clinical Medicine (IJCM) does not meet authors’ publication requirements. This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Please see the article page for more details. The full retraction notice in PDF is preceding the original paper which is marked "RETRACTED".
Cite this paper:   

[1]   Davies, L. and Welch, H. (2014) Current Thyroid Cancer Trends in the United States. JAMA Otolaryngology-Head & Neck Surgery, 140, 317-322.

[2]   Benhamiche, A.-M., Faivre, C., Minello, A., et al. (1998) Time Trends and Age-Period-Cohort Effects on the Incidence of Primary Liver Cancer in a Well-Defined French Population: 1976-1995. Journal of Hepatology, 29, 802-806.

[3]   Davies, L. and Welch, H. (2006) Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. The Journal of the American Medical Association, 295, 2164-2167.

[4]   Oh, C.-M., Jung, K.-W., Won, Y.-J., et al. (2015) Age-Period-Cohort Analysis of Thyroid Cancer Incidence in Korea. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 47, 362-369.

[5]   Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al. (2006) Survival and Death Causes in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism, 91, 313-319.

[6]   Cooper, D.S., Doherty, G.M., Haugen, B.R., et al. (2006) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 16, 109-142.

[7]   Pitoia, F., Bueno, F., Urciuoli, C., et al. (2013) Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems. Thyroid, 23, 1401-1407.

[8]   Vaisman, F., Momesso, D., Bulzico, D.A., et al. (2012) Spontaneous Remission in Thyroid Cancer Patients after Biochemical Incomplete Response to Initial Therapy. Clinical Endocrinology, 77, 132-138.

[9]   Jung, C.K., Little, M.P., Lubin, J.H., et al. (2014) The Increase in Thyroid Cancer Incidence during the Last Four Decades Is Accompanied by a High Frequency of BRAF Mutations and a Sharp Increase in RAS Mutations. Journal of Clinical Endocrinology & Metabolism, 99, E276-E285.

[10]   Aschebrook-Kilfoy, B., Kaplan, E.L., Chiu, B.C.-H., et al. (2013) The Acceleration in Papillary Thyroid Cancer Incidence Rates is Similar Among Racial and Ethnic Groups in the United States. Annals of Surgical Oncology, 20, 2746-2753.

[11]   Husson, O., Haak, H.R., van Steenbergen, L.N., et al. (2013) Rising Incidence, No Change in Survival and Decreasing Mortality from Thyroid Cancer in The Netherlands Since 1989. Endocrine-Related Cancer, 20, 263-271.

[12]   Davies, H., Bignell, G.R., Cox, C., et al. (2002) Mutations of the BRAF Gene in Human Cancer. Nature, 417, 949-954.

[13]   Xing, M. (2005) BRAF Mutation in Thyroid Cancer.. Endocrine-Related Cancer, 12, 245-262.

[14]   Nucera, C., Porrello, A., Antonello, Z.A., et al. (2010) B-RafV600E and Thrombospondin-1 Promote Thyroid Cancer Progression. Proceedings of the National Academy of Sciences, 107, 10649-10654.

[15]   Romei, C., Fugazzola, L., Puxeddu, E., et al. (2012) Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. The Journal of Clinical Endocrinology & Metabolism, 97, E1758-E1765.

[16]   Mathur, A., Moses, W., Rahbari, R., et al. (2011) Higher Rate of BRAF Mutation in Papillary Thyroid Cancer over Time. Cancer, 117, 4390-4395.

[17]   Lee, J.-H., Lee, E.-S. and Kim, Y.-S. (2007) Clinicopathologic Significance of BRAF V600E Mutation in Papillary Carcinomas of the Thyroid. Cancer, 110, 38-46.

[18]   Kim, Y.H., Yim, H., Lee, Y.-H., et al. (2016) Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens. Journal of Pathology and Translational Medicine, 50, 58-66.

[19]   Conzo, G., Avenia, N., Ansaldo, G.L., Calò, P., De Palma, M., et al. (2017) Surgical Treatment of Thyroid Follicular Neoplasms: Results of a Retrospective Analysis of a Large Clinical Series. Endocrine, 55, 530-538.

[20]   Marotta, V., Sciammarella, C., Capasso, M., Testori, A., Pivonello, C., et al. (2017) Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism, 102, 661-671.

[21]   Wan, P.T.C., Garnett, M.J., Roe, S.M., et al. (2004) Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 116, 855-867.

[22]   Elisei, R., Ugolini, C., Viola, D., et al. (2008) BRAF(V600E) Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study. Journal of Clinical Endocrinology & Metabolism, 93, 3943-3949.

[23]   Gear, H., Williams, H., Kemp, E.G., et al. (2004) BRAF Mutations in Conjunctival Melanoma. Investigative Ophthalmology & Visual Science, 45, 2484-2488.

[24]   Benlloch, S., Payá, A., Alenda, C., et al. (2006) Detection of BRAF V600E Mutation in Colorectal Cancer. The Journal of Molecular Diagnostics, 8, 540-543.

[25]   Chapman, P.B., Hauschild, A., Robert, C., et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. The New England Journal of Medicine, 364, 2507-2516.

[26]   Dietrich, S., Glimm Andrulis, H., et al. (2012) BRAF Inhibition in Refractory Hairy-Cell Leukemia. The New England Journal of Medicine, 366, 2038-2040.

[27]   Nehs, M.A., Nucera, C., Nagarkatti, S.S., et al. (2012) Late Intervention with Anti-BRAF(V600E) Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer. Endocrinology, 153, 985-994.

[28]   Schwartz, G.K., Robertson, S., Shen, A., et al. (2009) A Phase I Study of XL281, a Selective Oral RAF Kinase Inhibitor, in Patients (Pts) with Advanced Solid Tumors. Journal of Clinical Oncology, 27, 3513-3513.

[29]   Moses, W., Weng, J., Sansano, I., et al. (2010) Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-Needle Aspiration Biopsy. World Journal of Surgery, 34, 2589-2594.

[30]   Mathur, A., Weng, J., Moses, W., et al. (2010) A Prospective Study Evaluating the Accuracy of Using Combined Clinical Factors and Candidate Diagnostic Markers to Refine the Accuracy of Thyroid Fine Needle Aspiration Biopsy. Surgery, 148, 1170-1177.

[31]   Kim, T.H., Park, Y.J., Lim, J.A., et al. (2012) The Association of the BRAF(V600E) Mutation with Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer: A Meta-Analysis. Cancer, 118, 1764-1773.

[32]   Tufano, R.P., Teixeira, G.V., Bishop, J., et al. (2012) BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 91, 274-286.

[33]   Gray-Schopfer, V., Wellbrock, C. and Marais, R. (2007) Melanoma Biology and New Targeted Therapy. Nature, 445, 851-857.

[34]   Hong, T.L., et al. (2018) Relationship between BRAF(V600E) Gene Mutations and Clinicopathological Factors in 192 Thyroid Papillary Carcinomas. Journal of Xinjiang Medical University, No. 2.

[35]   Xu, H.W., et al. (2017) Relationship between BRAFV600E Gene Mutation and Central Lymph Node Metastasis in Cervical Lymph Node-Negative Thyroid Papillary Microcarcinoma. CJV, 17, 1277-1281.

[36]   Jin, W.D., et al. (2017) Detection of BRAFV600E Mutation in Papillary Thyroid Carcinoma Based on ARMS Method. Chinese Journal of Otorhinolaryngology Base, 24, 71-75.